This week, we’re reviewing the FDA full approval of a therapy for previously treated patients with advanced urothelial cancer. Then, we’ll hear about a trial that investigated potential mechanisms of acquired resistance to KRAS G12C inhibitors in patients with KRAS G12C–mutant cancers.

Coverage of stories discussed this week on ascopost.com:

FDA Grants Regular Approval to Enfortumab Vedotin-ejfv for Locally Advanced or Metastatic Urothelial Cancer

Mechanisms of Acquired Resistance to KRAS G12C Inhibition in Patients With Cancer

To listen to more podcasts from ASCO, visit asco.org/podcasts.